Lasser A, Vandenberg T L, Vincent M J, Hellstrom W J
Tulane University School of Medicine, New Orleans, La., USA.
J La State Med Soc. 1998 Sep;150(9):431-4.
We report our findings on the effects of intraplaque injection of verapamil for the treatment of Peyronie's disease. We followed 11 men with Peyronie's disease in a nonrandomized constant dose study. During our study, four men received testosterone supplementation; five received vitamin E and/or potassium aminobenzoate (potaba) concurrent with verapamil; two received injections of verapamil only. Plaque size decreased significantly in 7 of 11 patients (55%); softening occurred in 6 (55%); 4 of 8 patients (50%) had decreased curvature. Deformities and symptoms did not recur in any patients who reported improvement. Three of 11 (27%) patients failed treatment and elected to undergo surgical correction. All four (100%) of our study participants with pain had complete resolution after intraplaque verapamil injection compared with Levine et al's 91%. We have demonstrated that intraplaque verapamil injection is a promising treatment for Peyronie's disease in that it may circumvent surgical intervention and may be used with concurrent therapies.
我们报告了关于斑块内注射维拉帕米治疗佩罗尼氏病效果的研究结果。在一项非随机固定剂量研究中，我们跟踪了11名患有佩罗尼氏病的男性。在我们的研究中，4名男性接受了睾酮补充治疗；5名在接受维拉帕米治疗的同时还服用了维生素E和/或氨基苯甲酸酯钾（Potaba）；2名仅接受了维拉帕米注射。11名患者中有7名（55%）的斑块大小显著减小；6名（55%）出现了软化；8名患者中有4名（50%）的弯曲度减小。在报告病情有所改善的患者中，没有任何患者的畸形和症状复发。11名患者中有3名（27%）治疗失败并选择接受手术矫正。与莱文等人报告的91%相比，我们研究中所有4名（100%）有疼痛症状的参与者在斑块内注射维拉帕米后疼痛完全缓解。我们已经证明，斑块内注射维拉帕米是一种有前景的佩罗尼氏病治疗方法，因为它可能避免手术干预，并且可以与其他治疗方法同时使用。
